Jagsonpal Pharmaceuticals Ltd
Unaudited results along with its Limited Review Report for the quarter ended June 30, 2026
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 29 Jul 2026, 05:19 PM IST · BSE ID: 78148128-d27f-4e54-99f5-3059c93ac6e6
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's first-quarter profit increased by over 22%, and it also announced an agreement to buy another company.
🤖 AI Summary
- Jagsonpal Pharmaceuticals reported unaudited net profit of Rs. 131.89 Million for Q1 FY27, up 22.18% YoY.
- Revenue from operations for the quarter ended June 30, 2026, was Rs. 822.32 Million.
- Basic Earnings per Share (EPS) for Q1 FY27 stood at Rs. 2.00, compared to Rs. 1.60 in Q1 FY26.
- The company allotted 473,220 equity shares upon exercise of vested stock options during the quarter.
- An agreement was signed to acquire an 85% stake in Aequitas Healthcare Private Limited for Rs. 208 Million.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Net profit for the period/year
Rs. 131.89 Million
22.18%
Revenue from operations
Rs. 822.32 Million
8.76%
Total income
Rs. 850.65 Million
8.45%
Basic Earnings per share
Rs. 2.00
25.00%
Acquisition consideration (Aequitas Healthcare)
Rs. 208 Million
🏢 How This Affects the Company
The agreement to acquire an 85% equity stake in Aequitas Healthcare Private Limited indicates a potential expansion in its pharmaceutical product offerings and market presence, with existing promoters retaining a 15% stake and continuing management.
Net profit increased by Rs. 23.94 Million to Rs. 131.89 Million in Q1 FY27 from Rs. 107.95 Million in Q1 FY26. The acquisition of Aequitas Healthcare for Rs. 208 Million, funded through internal accruals, will impact future financial statements, as closing formalities were completed in July 2026.
The allotment of 473,220 equity shares through employee stock options indicates ongoing employee engagement strategies. The acquisition of Aequitas Healthcare may integrate new operational processes and product lines.
The company is evaluating the consequential impact of the Central Government's notified Code of Wages (Central) Rules, 2026, which may affect future employee benefit expenses.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take any immediate action based on this financial results announcement.
👤
Who Is Affected
Existing shareholders benefit from increased net profit and earnings per share. Equity shares allotted under ESOPs increase the total number of outstanding shares, affecting future EPS calculations.
🔍
Management Signal
Management is focused on growth through improved financial performance and strategic acquisitions, alongside ongoing employee incentivization through stock options.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — observe the continued growth in revenue and profit.
Updates on Aequitas Healthcare acquisition — monitor integration and financial impact.
Developments regarding new Labour Codes — assess any further accounting impacts.
MEDIUM RISK
While current results are positive, the impact of the acquisition and new labour codes on future financials requires monitoring.
💡 Investor Takeaway
Jagsonpal Pharmaceuticals reported Q1 FY27 unaudited net profit of Rs. 131.89 Million, an increase of 22.18% from Rs. 107.95 Million in Q1 FY26. Revenue from operations for the quarter was Rs. 822.32 Million, up from Rs. 756.12 Million in the prior year.
⚖️ Strengths & Concerns
✅ Positives
- Net profit for Q1 FY27 increased by 22.18% to Rs. 131.89 Million compared to Rs. 107.95 Million in Q1 FY26.
- Revenue from operations grew by 8.76% to Rs. 822.32 Million in Q1 FY27 from Rs. 756.12 Million in Q1 FY26.
⚠️ Concerns
- Cost of materials consumed for Q1 FY27 increased by 40.57% to Rs. 48.66 Million from Rs. 29.87 Million in the previous quarter (Q4 FY26).
- Employee benefits expense increased by 17.58% to Rs. 227.78 Million in Q1 FY27 compared to Rs. 194.41 Million in Q1 FY26.
📅 Company Track Record
Jagsonpal Pharmaceuticals reported a net profit increase of 22.18% to Rs. 131.89 Million in Q1 FY27, building on its previous Q1 FY26 net profit of Rs. 107.95 Million. Its Board previously met on July 29, 2026, to approve these Q1 FY27 financial results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Jagsonpal Pharmaceuticals' net profit for the quarter ended June 30, 2026?
Jagsonpal Pharmaceuticals reported an unaudited net profit of Rs. 131.89 Million for the quarter ended June 30, 2026.
How much did Jagsonpal Pharmaceuticals' revenue from operations grow in Q1 FY27?
Revenue from operations increased to Rs. 822.32 Million for Q1 FY27, up from Rs. 756.12 Million in Q1 FY26.
What was the Basic EPS for Jagsonpal Pharmaceuticals in Q1 FY27?
The Basic Earnings per Share (EPS) for Jagsonpal Pharmaceuticals was Rs. 2.00 for the quarter ended June 30, 2026.
What acquisition did Jagsonpal Pharmaceuticals announce?
Jagsonpal Pharmaceuticals entered into an agreement to acquire an 85% equity stake in Aequitas Healthcare Private Limited for a consideration of Rs. 208 Million.
What was the total comprehensive income for Jagsonpal Pharmaceuticals in Q1 FY27?
The total comprehensive income for Jagsonpal Pharmaceuticals for the quarter ended June 30, 2026, was Rs. 132.83 Million.
Questions based on this BSE filing only. For information purposes.